Tag: Alzheimer’s disease
Bristol Myers leads $237M round into Pathos AI platform
Pathos AI closed a $237M Series E led by Bristol Myers Squibb at a $3B valuation, adding Alzheimer's work to…
Korean AI wins FDA clearance to forecast Alzheimer’s risk
NeuroXT's NEXT-Cue scored 510(k) clearance to help clinicians estimate whether mild cognitive impairment will slide into dementia within five years.
INmune Bio taps Dirac-3S quantum machine to find new XPro uses
Quantum optimization, AI and conventional analytics will be applied under a collaboration announced by INmune Bio and Quantum Computing Inc.,…
Arrowhead’s RNA drug cuts Alzheimer’s tau by 73% in early trial
Arrowhead reported interim Phase 1/2a data showing its injectable RNA therapy crossed the blood-brain barrier and cut cerebrospinal tau by…
UCLA Health will run a national proving ground for dementia AI tools
The National Institute on Aging is funding a five-year national testing program led by UCLA Health with Mayo Clinic and…
Cortechs wins FDA nod for automated PET brain analysis
Cortechs.ai's NeuroQuant PET automates amyloid scan quantification after winning FDA 510(k) clearance.
Agentic AI roadmap aims to bring dementia expertise into primary care
Emory and UCSF researchers sketch a phased plan for agentic AI that brings specialist dementia care to primary clinics.